Stokes T C, Shaylor J M, O'Reilly J F, Harrison B D
Lancet. 1982 Aug 14;2(8294):345-8. doi: 10.1016/s0140-6736(82)90545-1.
A simple steroid trial was conducted to assess whether 31 patients with chronic airflow obstruction would benefit from oral steroid therapy. Peak expiratory flow (PEF), forced expired volume in 1 s (FEV1), and ratio of FEV1, to forced vital capacity (FVC) were monitored during a 6-month period (when patients were on maximum bronchodilator therapy), after 2 weeks on placebo and after 2 weeks on prednisolone 30 mg daily. Patients also measured that PEF at home thrice daily. None had a significant degree of steroid reversible airflow obstruction. The preliminary observation period (of at least 3 months) is important to prevent an improvement being attributed to steroids, when it has in fact occurred spontaneously or is the result of bronchodilator therapy or cessation of smoking.
进行了一项简单的类固醇试验,以评估31例慢性气流阻塞患者是否能从口服类固醇治疗中获益。在6个月期间(患者接受最大剂量支气管扩张剂治疗时)、服用安慰剂2周后以及服用泼尼松龙每日30毫克2周后,监测呼气峰值流速(PEF)、第1秒用力呼气量(FEV1)以及FEV1与用力肺活量(FVC)的比值。患者还在家中每天三次测量PEF。无一例患者存在显著程度的类固醇可逆性气流阻塞。初步观察期(至少3个月)很重要,可防止将实际上自发出现、或由支气管扩张剂治疗或戒烟导致的改善归因于类固醇。